AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1455811 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined action of bitemporal UHF electric field and decimeter waves
Number of subjects: 0
Study 3967455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg amantadine)
Number of subjects: 74
Study 3967455 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg amantadine
Number of subjects: 74
Study 3967455 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg amantadine
Number of subjects: 74
Study 3967455 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg amantadine
Number of subjects: 74
Study 29588170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lira‐basal (0.9 mg/day liraglutide plus basal insulin)
Number of subjects: 50
Study 29588170 — intervention group
Group type: COMPARATOR
Intervention: BBIT (basal-bolus insulin therapy)
Number of subjects: 50
Study 28472303 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training (3 × 3 minutes twice daily for 5 months)
Number of subjects: 24
Study 28472303 — intervention group
Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 24
Study 25445405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook. f. (TwHF) 1.5 mg/kg/day
Number of subjects: 90
Study 25445405 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine 2.0 mg/kg/day
Number of subjects: 90
Study 23439102 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 23439102 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1800
Study 23439102 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (low SYNTAX scores)
Number of subjects: 1800
Study 23439102 — intervention group
Group type: COMPARATOR
Intervention: PCI (low SYNTAX scores)
Number of subjects: 1800
Study 23439102 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (left main coronary disease)
Number of subjects: 1800
Study 23439102 — intervention group
Group type: COMPARATOR
Intervention: PCI (left main coronary disease)
Number of subjects: 1800
Study 23439102 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (intermediate SYNTAX scores)
Number of subjects: 1800
Study 23439102 — intervention group
Group type: COMPARATOR
Intervention: PCI (intermediate SYNTAX scores)
Number of subjects: 1800
Study 23439102 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (high SYNTAX scores)
Number of subjects: 1800
Study 23439102 — intervention group
Group type: COMPARATOR
Intervention: PCI (high SYNTAX scores)
Number of subjects: 1800
Study 21386986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ne-IC (Independent Component) in older subjects
Number of subjects: 2
Study 21386986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ne-IC contribution in older subjects
Number of subjects: 2
Study 21386986 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction Time (RT) distribution parameters
Number of subjects: 2
Study 21386986 — intervention group
Group type: EXPERIMENTAL
Intervention: General behavior of older participants
Number of subjects: 2
Study 21386986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ne decline in elderly
Number of subjects: 2
Study 18376221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd-103 brachytherapy
Number of subjects: 602
Study 18376221 — intervention group
Group type: COMPARATOR
Intervention: I-125 brachytherapy
Number of subjects: 602
Study 17557467 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Number of subjects: 35
Study 17557467 — intervention group
Group type: COMPARATOR
Intervention: Information-Only Control (IC)
Number of subjects: 35
Study 14696664 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained overdenture (IRO)
Number of subjects: 121
Study 14696664 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 121
Study 14696664 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosseous implants
Number of subjects: 121
Study 10361178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection (UD) group (n = 27)
Number of subjects: 58
Study 10361178 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CV) group (n = 31)
Number of subjects: 58
Study 8697067 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 50 mg three times a day
Number of subjects: 0
Study 8697067 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 10 mg, 60 mg, and 120 mg three times a day
Number of subjects: 0
Study 8697067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8697067 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 1781526 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 1:200,000 administered 5 minutes before 20 ml bupivacaine 0.5%
Number of subjects: 24
Study 1781526 — intervention group
Group type: COMPARATOR
Intervention: Saline followed by 20 ml bupivacaine 0.5% with 100 micrograms adrenaline
Number of subjects: 24
Study 1781526 — intervention group
Group type: COMPARATOR
Intervention: Saline followed by 20 ml plain bupivacaine 0.5%
Number of subjects: 24
Study 7014790 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (5 mg/kg/day of methylprednisolone)
Number of subjects: 100
Study 7014790 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid group (no drug)
Number of subjects: 100
Study 31094229 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation
Number of subjects: 36
Study 31094229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cooling
Number of subjects: 36
Study 31094229 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with pre-cooling
Number of subjects: 36
Study 31094229 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 30304936 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact within 2-4 days of release by a continuity clinic coordinator, who scheduled and informed the ex-detainees of their appointment date within 6 weeks post-release plus standard of care.
Number of subjects: 110
Study 30304936 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (comprehensive discharge planning, offering substance abuse treatment, provision of information on self-scheduling appointments).
Number of subjects: 110
Study 27091235 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting group (5 min after peri-prostatic nerve block)
Number of subjects: 92
Study 27091235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no waiting after peri-prostatic nerve block)
Number of subjects: 92
Study 27091235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 25503600 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 5, 10, and 20 μg/h (maximum dosage of 20 μg/h)
Number of subjects: 280
Study 25503600 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release tramadol tablets 100 mg (maximum dosage of 400 mg/d)
Number of subjects: 280
Study 23792641 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-3512676 (0.20 mg/kg injected subcutaneously once weekly) plus erlotinib (150 mg daily)
Number of subjects: 39
Study 23792641 — intervention group
Group type: COMPARATOR
Intervention: erlotinib alone (150 mg daily)
Number of subjects: 39
Study 23792641 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-3512676 plus erlotinib
Number of subjects: 39
Study 23792641 — intervention group
Group type: COMPARATOR
Intervention: erlotinib alone
Number of subjects: 39
Study 22929598 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven quality improvement in primary care (DQIP) intervention
Number of subjects: 0
Study 22929598 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19762706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic, catheter‐based normothermia (CoolGard; body core temperature 36.5 degrees C)
Number of subjects: 102
Study 19762706 — intervention group
Group type: COMPARATOR
Intervention: Conventional, stepwise fever management with anti‐inflammatory drugs and surface cooling
Number of subjects: 102
Study 19762706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic normothermia
Number of subjects: 102
Study 18161263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 0
Study 15204145 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 microg/g ointment twice daily for 12 weeks
Number of subjects: 31
Study 15204145 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 0.1% ointment twice daily for 12 weeks
Number of subjects: 31
Study 15204145 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessment using visual analogue scales (VAS)
Number of subjects: 31
Study 15204145 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events with calcipotriol
Number of subjects: 31
Study 11816702 — intervention group
Group type: EXPERIMENTAL
Intervention: danaparoid
Number of subjects: 42
Study 11816702 — intervention group
Group type: COMPARATOR
Intervention: dextran 70
Number of subjects: 42
Study 9648983 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication (omeprazole plus clarithromycin and tinidazole for 1 week)
Number of subjects: 38
Study 9648983 — intervention group
Group type: COMPARATOR
Intervention: Control (full-dose ranitidine for 3 weeks)
Number of subjects: 38
Study 9403153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambridge Contextual Reading Test (CCRT)
Number of subjects: 30
Study 9403153 — intervention group
Group type: COMPARATOR
Intervention: National Adult Reading Test (NART)
Number of subjects: 30
Study 2019185 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg qid)
Number of subjects: 80
Study 2019185 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (40 mg bid)
Number of subjects: 80
Study 7046974 — intervention group
Group type: EXPERIMENTAL
Intervention: IV and oral metoclopramide
Number of subjects: 117
Study 7046974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 117
Study 31270220 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 210
Study 31270220 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 210
Study 31270220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 29186633 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered intervention program (FCIP)
Number of subjects: 251
Study 26363164 — intervention group
Group type: EXPERIMENTAL
Intervention: NS+budesonide irrigations
Number of subjects: 50
Study 26363164 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) irrigations
Number of subjects: 50
Study 23530576 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 50 mg once daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily 30 min before meals (Group A)
Number of subjects: 60
Study 23530576 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 50 mg three times daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily immediately before meals (Group C)
Number of subjects: 60
Study 23530576 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 50 mg three times daily plus isophane protamine biosynthetic human insulin 70/30 injections twice daily 30 min before meals (Group B)
Number of subjects: 60
Study 21521342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen C (10 mg mane/5 mg tarde)
Number of subjects: 10
Study 21521342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen A (20 mg mane/10 mg tarde)
Number of subjects: 10
Study 21521342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen B (10 mg mane/10 mg tarde)
Number of subjects: 10
Study 21521342 — intervention group
Group type: EXPERIMENTAL
Intervention: All hydrocortisone regimens
Number of subjects: 10
Study 21521342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen C (10 mg/5 mg)
Number of subjects: 10
Study 18922087 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychromatic visible (pVIS) light exposure (385-750 nm, 95% polarization, 40 mW/cm2, 12 J/cm2) for 5 min
Number of subjects: 42
Study 18922087 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychromatic visible (pVIS) light exposure (385-750 nm, 95% polarization, 40 mW/cm2, 12 J/cm2) with NOS inhibitor (L-NMMA, 0.1% solution) administered iontophoretically prior to exposure
Number of subjects: 42
Study 18922087 — intervention group
Group type: COMPARATOR
Intervention: Control group with NOS inhibitor (L-NMMA, 0.1% solution) administered to the non-irradiated hand
Number of subjects: 42
Study 18922087 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated hand (systemic effect)
Number of subjects: 42
Study 16217756 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 mcg of selenized yeast)
Number of subjects: 598
Study 12946034 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 1905
Study 12946034 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (more than 325 mg per day)
Number of subjects: 1905
Study 11119197 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane and IV dexamethasone (n=188)
Number of subjects: 569
Study 11119197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (n=201)
Number of subjects: 569
Study 11119197 — intervention group
Group type: COMPARATOR
Intervention: Halothane (n=180)
Number of subjects: 569
Study 8894061 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MD) patients
Number of subjects: 0
Study 8894061 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizotypal personality disorder (STP) patients
Number of subjects: 0
Study 8894061 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 1824752 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School intervention (exercise and education)
Number of subjects: 74
Study 1824752 — intervention group
Group type: COMPARATOR
Intervention: Counseling intervention
Number of subjects: 74
Study 6132935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1.0 mg)
Number of subjects: 0
Study 6132935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1/6 or 1/2 gill of vodka, equal to 6.5 or 19.6 g)
Number of subjects: 0
Study 6132935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1/6 or 1/2 gill of vodka)
Number of subjects: 0
Study 6132935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1.0 mg) + Alcohol (1/6 or 1/2 gill of vodka)
Number of subjects: 0
Study 6132935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30912231 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (25(OH)D) for 12 weeks
Number of subjects: 23
Study 30912231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 28209298 — intervention group
Group type: EXPERIMENTAL
Intervention: Utidelone plus capecitabine
Number of subjects: 405
Study 28209298 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 405
Study 26435334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 56
Study 26435334 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 56
Study 26435334 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 25218194 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402 (single dose)
Number of subjects: 57
Study 25218194 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402 (two doses)
Number of subjects: 57
Study 25218194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 22068700 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced propofol sedation (BPS)
Number of subjects: 110
Study 22068700 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation
Number of subjects: 110
Study 19173175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative training using the Viv-Arte model based on kinesthetic mobilisation principles
Number of subjects: 27
Study 19173175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-operative training)
Number of subjects: 27
Study 17701875 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of intracerebral hemorrhage
Number of subjects: 0
Study 17701875 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent advances in management (i.e., STICH trial and recombinant factor VII trial)
Number of subjects: 0
Study 15218298 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 i.v. over 1 h followed by gemcitabine 2,000 mg/m2 biweekly until progression or intolerable toxicity
Number of subjects: 32
Study 12034152 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-effects model
Number of subjects: 298
Study 12034152 — intervention group
Group type: COMPARATOR
Intervention: MANOVA model
Number of subjects: 298
Study 9879342 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin
Number of subjects: 0
Study 9879342 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 9879342 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 8602597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering dietary intervention
Number of subjects: 784
Study 8602597 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 784
Study 8602597 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E phenotype
Number of subjects: 784
Study 2913248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine; lidocaine, diazepam, and meperidine; lidocaine, diazepam, meperidine, and headphone music; lidocaine, diazepam, meperidine, and nitrous oxide; lidocaine, diazepam, meperidine, methohexital, and nitrous oxide; lidocaine and nitrous oxide
Number of subjects: 60
Study 2913248 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen
Number of subjects: 60
Study 2913248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine anesthesia
Number of subjects: 60
Study 1124050 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 puffs of Sch 1000 administered 6 times
Number of subjects: 10
Study 1124050 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenalin
Number of subjects: 10
Study 1124050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31710095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1000 mg twice daily for 12 weeks
Number of subjects: 40
Study 31710095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31325288 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth system for secondary prevention of stroke
Number of subjects: 637
Study 28365804 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 108
Study 28365804 — intervention group
Group type: COMPARATOR
Intervention: TachoComb
Number of subjects: 108
Study 25190154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentive (CNY 10)
Number of subjects: 0
Study 25190154 — intervention group
Group type: COMPARATOR
Intervention: No cash incentive
Number of subjects: 0
Study 23343798 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (100U in 10 mL) via cystoscopy
Number of subjects: 21
Study 23343798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 21
Study 21270188 — intervention group
Group type: EXPERIMENTAL
Intervention: u-healthcare (n = 49)
Number of subjects: 144
Study 21270188 — intervention group
Group type: EXPERIMENTAL
Intervention: self-monitored blood glucose (SMBG) (n = 47)
Number of subjects: 144
Study 21270188 — intervention group
Group type: COMPARATOR
Intervention: routine care (control, n = 48)
Number of subjects: 144
Study 19320570 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV/r100
Number of subjects: 115
Study 16376562 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of air in the venous cannula
Number of subjects: 135
Study 16376562 — intervention group
Group type: COMPARATOR
Intervention: Absence of retained air in the venous cannula
Number of subjects: 135
Study 16376562 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of air in the venous cannula
Number of subjects: 135
Study 14964337 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter irritation applied to the left hand using a submaximal effort tourniquet procedure
Number of subjects: 20
Study 14964337 — intervention group
Group type: COMPARATOR
Intervention: No counter irritation
Number of subjects: 20
Study 11524357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP)
Number of subjects: 80
Study 11524357 — intervention group
Group type: COMPARATOR
Intervention: Control (simple placement of hands without exerting pressure)
Number of subjects: 80
Study 9250256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 337.5 mg b.i.d.
Number of subjects: 65
Study 9250256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 450 mg b.i.d.
Number of subjects: 65
Study 9250256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 8502270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g of oil per day, containing 5 g of eicosapentaenoic and docosahexaenoic acid)
Number of subjects: 145
Study 8502270 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (isoenergetic amount containing mainly n-6 fatty acids)
Number of subjects: 145
Study 3568535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid pretreatment
Number of subjects: 20
Study 3568535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28710873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg per day
Number of subjects: 128
Study 28710873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 26955311 — intervention group
Group type: EXPERIMENTAL
Intervention: Precaine gel
Number of subjects: 83
Study 26955311 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine topical paste
Number of subjects: 83
Study 26955311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine spray
Number of subjects: 83
Study 26955311 — intervention group
Group type: COMPARATOR
Intervention: Control (no topical anesthetic)
Number of subjects: 83